{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:21:30Z","timestamp":1782800490018,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.02.019","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T15:48:54Z","timestamp":1613922534000},"page":"1721-1726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pneumococcal polysaccharide vaccine is a cost saving strategy for prevention of acute coronary syndrome"],"prefix":"10.1016","volume":"39","author":[{"given":"Shu","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-1308","authenticated-orcid":false,"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Chuen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-6636","authenticated-orcid":false,"given":"David","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.019_b0005","unstructured":"Australian Institute of Health and Welfare. Deaths in Australia. Canberra: AIHW; 2019."},{"key":"10.1016\/j.vaccine.2021.02.019_b0010","unstructured":"National Heart Foundation of Australia. Economic Cost of Acute Coronary Syndrome in Australia: The Cost to Governments. In: Melbourne: National Heart Foundation of Australia; 2018."},{"key":"10.1016\/j.vaccine.2021.02.019_b0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1741-7015-11-117","article-title":"Immunity, atherosclerosis and cardiovascular disease","volume":"11","author":"Frostegard","year":"2013","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.vaccine.2021.02.019_b0020","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nm876","article-title":"Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL","volume":"9","author":"Binder","year":"2003","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2021.02.019_b0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jacc.2006.11.054","article-title":"Phosphorylcholine-targeting immunization reduces atherosclerosis","volume":"50","author":"Caligiuri","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.019_b0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2005.11.033","article-title":"Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice","volume":"189","author":"Faria-Neto","year":"2006","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.vaccine.2021.02.019_b0035","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/01.CIR.0000143162.56057.B5","article-title":"Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis","volume":"110","author":"Schiopu","year":"2004","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.vaccine.2021.02.019_b0040","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2007.07.081","article-title":"Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1\u2212\/\u2212\/low-density lipoprotein receptor\u2212\/\u2212 mice","volume":"50","author":"Schiopu","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"10.1016\/j.vaccine.2021.02.019_b0045","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.vaccine.2012.03.084","article-title":"Pneumococcal vaccination may induce anti-oxidized low-density lipoprotein antibodies that have potentially protective effects against cardiovascular disease","volume":"30","author":"Suthers","year":"2012","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2021.02.019_b0050","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/heartjnl-2012-301743","article-title":"Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study","volume":"98","author":"Eurich","year":"2012","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.vaccine.2021.02.019_b0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1503\/cmaj.070221","article-title":"Pneumococcal vaccination and risk of myocardial infarction","volume":"179","author":"Lamontagne","year":"2008","journal-title":"CMAJ"},{"issue":"15","key":"10.1016\/j.vaccine.2021.02.019_b0060","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1503\/cmaj.091891","article-title":"Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study","volume":"182","author":"Siriwardena","year":"2010","journal-title":"CMAJ"},{"issue":"17","key":"10.1016\/j.vaccine.2021.02.019_b0065","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/jama.2010.529","article-title":"Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men","volume":"303","author":"Tseng","year":"2010","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.019_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000247","article-title":"Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis","volume":"2","author":"Ren","year":"2015","journal-title":"Open Heart"},{"issue":"49","key":"10.1016\/j.vaccine.2021.02.019_b0075","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1016\/j.vaccine.2018.10.064","article-title":"Pneumococcal polysaccharide vaccine associated with reduced lengths of stay for cardiovascular events hospital admissions: experience from the hunter community study","volume":"36","author":"Ren","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.019_b0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ahj.2016.04.003","article-title":"Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: the Australian study for the prevention through immunization of cardiovascular events (AUSPICE)","volume":"177","author":"Ren","year":"2016","journal-title":"Am Heart J"},{"issue":"9","key":"10.1016\/j.vaccine.2021.02.019_b0085","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5694\/mja2.50117","article-title":"Evaluating recruitment strategies for AUSPICE, a large Australian community-based randomised controlled trial","volume":"210","author":"Peel","year":"2019","journal-title":"Med J Aust"},{"issue":"48","key":"10.1016\/j.vaccine.2021.02.019_b0090","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.019_b0095","unstructured":"Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases, 12th ed., 2012. p. 233\u201348. https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/pneumo.pdf."},{"key":"10.1016\/j.vaccine.2021.02.019_b0100","unstructured":"Department of Health. Australian immunisation handbook \u2013 pneumococcal disease. https:\/\/immunisationhandbook.health.gov.au\/vaccine-preventable-diseases\/pneumococcal-disease."},{"key":"10.1016\/j.vaccine.2021.02.019_b0105","unstructured":"Australian Institute of Health and Welfare. 2009 adult vaccination survey: summary results. Canberra: AIHW; 2011."},{"key":"10.1016\/j.vaccine.2021.02.019_b0110","unstructured":"Centre for Epidemiology and Evidence. HealthStats NSW. Influenza and pneumococcal disease immunisation: 65 and over*, NSW 2002-2003 to 2016-2017. Sydney: NSW Ministry of Health."},{"key":"10.1016\/j.vaccine.2021.02.019_b0115","unstructured":"Department of Health. Proposed changes to the recommended use of pneumococcal vaccines. https:\/\/consultations.health.gov.au\/ohpd-health-protection-policy-branch\/pneumococcal-vaccine\/."},{"key":"10.1016\/j.vaccine.2021.02.019_b0120","unstructured":"Department of Health. Pharmaceutical Benefits Advisory Committee Guidelines \u2013 3A.1 Overview and rationale of the economic evaluation. https:\/\/pbac.pbs.gov.au\/section-3a\/3a-1-overview-and-rationale-of-economic-evaluation.html."},{"issue":"2","key":"10.1016\/j.vaccine.2021.02.019_b0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.hlc.2017.10.015","article-title":"All-cause mortality following an acute coronary syndrome: 12-year follow-up of the comprehensive 2002 New Zealand acute coronary syndrome audit","volume":"28","author":"Ellis","year":"2019","journal-title":"Heart Lung Circul"},{"key":"10.1016\/j.vaccine.2021.02.019_b0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12913-015-0772-9","article-title":"Acute and chronic impact of cardiovascular events on health state utilities","volume":"15","author":"Matza","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vaccine.2021.02.019_b0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.vhri.2015.03.015","article-title":"Quality of life among patients with acute coronary syndrome in Malaysia","volume":"6","author":"Azmi","year":"2015","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.019_b0140","doi-asserted-by":"crossref","first-page":"e000419","DOI":"10.1136\/openhrt-2016-000419","article-title":"Health utility indexes in patients with acute coronary syndromes","volume":"3","author":"Gencer","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.vaccine.2021.02.019_b0145","unstructured":"Department of Health. Pharmaceutical benefits scheme \u2013 pneumococcal purified capsular polysaccharides. http:\/\/www.pbs.gov.au\/medicine\/item\/10210J [accessed Jan 2020]."},{"key":"10.1016\/j.vaccine.2021.02.019_b0150","unstructured":"Department of Health. Medicare benefits schedule \u2013 note GN.12.32. http:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=note&q=GN.12.32&qt=noteID&criteria=vaccination [accessed Jan 2020]."},{"key":"10.1016\/j.vaccine.2021.02.019_b0155","unstructured":"Australian Bureau of Statistics. Causes of death, Australia, 2016; 2017."},{"key":"10.1016\/j.vaccine.2021.02.019_b0160","unstructured":"AHFS Drug Information\u00ae \u2013 2019th ed. \u2013 pneumococcal vaccine. AmericanSocietyofHealth-SystemPharmacists."},{"key":"10.1016\/j.vaccine.2021.02.019_b0165","first-page":"A68","article-title":"Allergic hypersensitivity to the 23-valent pneumococcalvaccine: a case report","volume":"1","author":"McCormick","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.vaccine.2021.02.019_b0170","unstructured":"Commonwealth of Australia as represented by the Department of Health. National immunisation strategy for Australia 2019 to 2024. Department of Health, Canberra; 2019."},{"key":"10.1016\/j.vaccine.2021.02.019_b0175","unstructured":"Australian Institute of Health and Welfare. Older Australia at a glance. Canberra: AIHW; 2018."},{"issue":"36","key":"10.1016\/j.vaccine.2021.02.019_b0180","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"Ogilvie","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.019_b0185","first-page":"Cd000422","article-title":"Vaccines for preventing pneumococcal infection in adults","volume":"201","author":"Moberley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.vaccine.2021.02.019_b0190","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.019_b0195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2021.02.019_b0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5694\/mja12.11759","article-title":"Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older","volume":"200","author":"Menzies","year":"2014","journal-title":"Med J Aust"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:53:16Z","timestamp":1759402396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21001675"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumococcal polysaccharide vaccine is a cost saving strategy for prevention of acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}